Dr Michael Buschle
Chief Scientific Officer, Glenmark Pharmaceuticals Ltd.
|
Education
Doctorate
University Of London
Other Affiliations
Local Address: La Chaux-de-Fonds, Switzerland
Dr. Michael Buschle has been Chief Scientific Officer of Glenmark Pharmaceuticals Ltd. Dr. Buschle serves as President for Biologics Research at Glenmark Pharmaceuticals S.A.
He served as President for Biologics Research at Glenmark Pharmaceuticals Ltd. Mr. Buschle served as Chief Scientific Officer of Intercell Biomedical Research & Development AG. Dr. Buschle served as Director and Managing Director of Intercell Biomedical Ltd., a subsidiary of Intercell AG.
He served
Dr Michael Buschle
Dr Michael Buschle
Mr. Buschle scientific and industrial career includes work at Royal Free Hospital School of Medicine, London, UK, the St. Jude Children’s Research Hospital, Memphis, TN, USA and at pharmaceutical company Boehringer Ingelheim. He was one of the co-founders of Intercell AG. During his time at Boehringer Ingelheim, he was involved in the development of a cancer vaccine against malignant melanomas. Mr. Buschle is the holder of several patents in the field of vaccines and biotechnology.
Mr. Buschle is responsible for its Core Research activities leading to development candidates. Dr. Buschle has over 12 years of pharmaceutical/biotech industry experience in areas including drug research and development and biopharmaceuticals manufacturing. Dr. Buschle holds a doctorate from the University of London.
Dr Anthony crasto With Dr Michael Buschle end 2014
Company Description:
Glenmark US Operations Glenmark Pharmaceuticals has established its US subsidiary, based in Princeton, New Jersey, Glenmark Pharmaceuticals Inc., USA, to help file ANDAs and market finished formulations in the lucrative US market. Glenmark Pharmaceuticals Inc., USA will file Paragraph III and Paragraph IV ANDA filings for approval to market generic drugs, and work in tandem with other companies in marketing partnerships, to establish market penetration and substantial marketshare in the US market. Glenmark will make a number of such filings over the next 18 to 24 months. Further the company will register its bulk drugs - the key ingredients that lend medicines their potency - with the US Food & Drug Administration. It plans four to five drug master filings in the US this year, with the first likely to happen in the second quarter ending September. With these strategic initiatives underway, the Company is aggressively looking at additional strategic partnerships with other leading generic drug companies with a strong US presence.
//////////////
CLICK TO PLAY
Published on 21 Aug 2014
Mint met with Michael Buschle, Chief Scientific Officer & President of Biologics, Glenmark Pharmaceuticals to discuss costs, challenges and selecting regions for trials in India.
“Researchers at Glenmark focus on developing monoclonal antibodies. Glenmark is the first Indian company that has a novel, first-in-class novel biologic entity in the clinics in the US. We are establishing platform technologies to develop biologics in a format specific for Glenmark”
-Dr Michael Buschle, president (biologics), Glenmark Pharmaceuticals- See more at: http://www.biospectrumindia.com/biospecindia/news/158971/master-innovation#sthash.k9A3A07N.dpuf
PICTURES
SWITZERLAND
Mahwah , New Jersey
dollar 22 Million English Manor in Mahwah New Jersey
La Chaux-de-Fonds, Switzerland
No comments:
Post a Comment